Nan Young Lee

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies

Natural killer cell therapies

Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation Outcomes in Patients with Hematologic Malignancies after Allogeneic Peripheral Stem Cell Transplantation

Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non‐relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA‐matched sibling donors